The goal of this randomized case-control study is to analysis of effectiveness of tigecycline in scrub typhus. The main question it aims to answer are: * \[question 1\]: Does tigecycline reduce fever faster than doxycycline in scrub typhus? * \[question 2\]: Is the use of tigecylcine tolerable in scrub typhus? Participants will assigned as doxycycline or tigecycline groups. Researchers will compare tigecycline group with doxycycline group, using defervescence time and adverse events.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
31
Doxycycline 100 mg orally every 12 hours for 7 days.
Tigecycline 100 mg intravenously as a loading dose, followed by 50 mg intravenously every 12 hours for 5 days.
Dankuk university hospital
Cheonan, Chungcheongnam-do, South Korea
Inha university hospital
Incheon, South Korea
Gyeonsang National University Hospital
Jinju, South Korea
Defervescence
Time from treatment initiation to defervescence, defined as maintenance of body temperature below 37.3°C for at least 48 consecutive hours without antipyretics.
Time frame: from treatment initiation to defervescence, assessed daily through Day 7
Treatment failure
persistence of fever over 3 days after therapy, but no other cause of fever
Time frame: up to 7 days after treatment initiation
Relapse
relapse on 30th days
Time frame: up to 30 days after treatment initiation
adverse events
Occurrence of treatment-emergent adverse events
Time frame: up to 28 days after treatment initiation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.